Healthcare utilisation and costs associated with adding montelukast to current therapy in patients with mild to moderate asthma and co-morbid allergic rhinitis - PRAACTICAL study

被引:12
|
作者
Dal Negro, Roberto
Piskorz, Peter
Vives, Roberto
Guilera, Magda
Kocevar, Vasilisa Sazonov
Badia, Xavier
机构
[1] Bussolengo Gen Hosp, Lung Dept, Verona, Italy
[2] Outpatient Clin, Dept Pneumol, Wotomin, Poland
[3] Hosp 12 Octubre, Dept Allergol, E-28041 Madrid, Spain
[4] IMS Hlth, Hlth Outcomes Res Europe Prior, Barcelona, Spain
[5] Merck & Co Inc, Outcomes Res, Whitehouse Stn, NJ USA
关键词
D O I
10.2165/00019053-200725080-00004
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective: To evaluate the healthcare resource use and costs associated with adding montelukast to therapy in patients with mild to moderate persistent asthma and co-morbid seasonal allergic rhinitis whose asthma is inadequately controlled by their current asthma therapy. Methods: A multicentre, pre-post retrospective cohort study was conducted in three European countries (Italy, Poland and Spain). Consecutive patients who were receiving inhaled corticosteroid therapy (monotherapy or combination therapy with long-acting beta(2)-adrenoceptor agonists) and who started concomitant treatment with montelukast between January 1999 and December 2002 were identified from clinical charts. Asthma/seasonal allergic rhinitis-related concomitant medications and asthma-related Outpatient care, ED visits and hospitalisations for the periods 12 months before and 12 months after montelukast initiation were recorded from patient charts and combined with country-specific published unit costs (adjusted to 2004 values). The analysis was performed from a third-party-payer perspective and thus direct healthcare resource utilisation due to asthma/ seasonal allergic rhinitis and associated costs for each country were estimated. Results: A total of 98 physicians provided data for 696 asthmatic patients with seasonal allergic rhinitis (Italy: n = 158; Poland: n = 334; and Spain: n = 204). The mean age of patients was 32.7 years, 57.5% were female and patients had asthma that was considered either mild-persistent (54.5%) or moderate-persistent (45.5%) according to the Global Initiative for Asthma classifications. The introduction of montelukast (10 mg/day daily cost range is an element of 0.8-1.68) was associated with increases in the total annual mean healthcare cost per patient of 11.9%, 60.4% and 5.5% for Italy, Poland and Spain, respectively. However, mean annual costs for asthma-related outpatient care, ED visits and hospitalisations dropped significantly in all three countries (Italy: from is an element of 805.00 to is an element of 281.60 [p < 0.01]; Poland: from is an element of 127.10 to is an element of 99.00 [p < 0.01]; and Spain: from is an element of 463.40 to is an element of 119.70 [p < 0.01]). Conclusions: The addition of montelukast to therapy in patients with mild to moderate asthma and concomitant seasonal allergic rhinitis whose asthma was inadequately controlled by current asthma therapy significantly reduced the use of concomitant asthma-allergy medications, ED visits, outpatient care visits and hospitalisation. The total direct healthcare cost obtained after the addition of montelukast increased only as a result of the montelukast treatment cost.
引用
收藏
页码:665 / 676
页数:12
相关论文
共 11 条
  • [1] Healthcare Utilisation and Costs Associated with Adding Montelukast to Current Therapy in Patients with Mild to Moderate Asthma and Co-Morbid Allergic RhinitisPRAACTICAL Study
    Roberto Dal Negro
    Peter Piskorz
    Roberto Vives
    Magda Guilera
    Vasilisa Sazonov Kocevar
    Xavier Badia
    [J]. PharmacoEconomics, 2007, 25 : 665 - 676
  • [2] AN EXAMINATION OF THE EFFICACY OF CICLESONIDE IN MILD-TO-MODERATE ASTHMA PATIENTS WITH AND WITHOUT CO-MORBID ALLERGIC RHINITIS.
    Kerwin, E.
    Claus, R.
    Karafilidis, J.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2009, 103 (05) : A67 - A67
  • [3] An analysis of inadequately controlled asthma patients with and without co-morbid allergic rhinitis treated with add-on montelukast
    Virchow, J.
    Mehta, A.
    Ljungblad, L.
    Mitfessel, H.
    [J]. ALLERGY, 2009, 64 : 183 - 183
  • [4] Management of co-morbid allergic rhinitis and asthma in a low and middle income healthcare setting
    Yusuf, Osman Mohammad
    [J]. PRIMARY CARE RESPIRATORY JOURNAL, 2012, 21 (02): : 228 - 230
  • [5] Impact of montelukast therapy on asthma-related health care resources use in mild to moderate asthmatic patients with seasonal allergic rhinitis in Spain
    Blázquez, JAP
    Redondo, RB
    Kocevar, VS
    Badia, X
    Guilera, M
    Caloto, MT
    Nocea, G
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A31 - A31
  • [6] Utilisation of an environmental challenge chamber (ECC) to explore allergen induced bronchial hyperresponsiveness (BHR) in mild asthmatic patients with co-morbid rhinitis
    Krug, N
    Hohlfeld, JM
    Bruns, H
    Russell, P
    Weeks, A
    Larbig, M
    Murdoch, RD
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2006, 117 (02) : S3 - S3
  • [7] Concomitant bilastine and montelukast as additive therapy for seasonal allergic rhinoconjunctivits and mild-to-moderate asthma. The SKY study
    Lavorini, Federico
    Matucci, Andrea
    Rossi, Oliviero
    Pistolesi, Massimo
    [J]. ALLERGY, 2020, 75 (03) : 675 - 678
  • [8] Asthma control in patients with asthma and allergic rhinitis receiving add-on montelukast therapy for 12 months: a retrospective observational study
    Borderias, Luis
    Mincewicz, Grzegorz
    Paggiaro, Pier Luigi
    Guilera, Magda
    Kocevar, Vasilisa Sazonov
    Taylor, Stephanie D.
    Badia, Xavier
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (04) : 721 - 730
  • [9] A Randomized, Multicenter, Double-blind, Phase III Study to Evaluate the Efficacy on Allergic Rhinitis and Safety of a Combination Therapy of Montelukast and Levocetirizine in Patients With Asthma and Allergic Rhinitis
    Kim, Mi-Kyeong
    Lee, Sook Young
    Park, Hae-Sim
    Yoon, Ho Joo
    Kim, Sang-Ha
    Cho, Young Joo
    Yoo, Kwang-Ha
    Lee, Soo-Keol
    Kim, Hee-Kyoo
    Park, Jung-Won
    Park, Heung-Woo
    Chung, Jin-Hong
    Choi, Byoung Whui
    Lee, Byung-Jae
    Chang, Yoon-Seok
    Jo, Eun-Jung
    Lee, Sang-Yeub
    Cho, You Sook
    Jee, Young-Koo
    Lee, Jong-Myung
    Jung, Jina
    Park, Choon-Sik
    [J]. CLINICAL THERAPEUTICS, 2018, 40 (07) : 1096 - 1107
  • [10] A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A COMBINATION THERAPY OF MONTELUKAST AND LEVOCETIRIZINE IN PATIENTS WITH ASTHMA AND ALLERGIC RHINITIS
    Park, Jong Sook
    Park, Choon-Sik
    Cho, Young Joo
    Choi, Byoung Whui
    [J]. CHEST, 2018, 154 (04) : 1120A - 1120A